Black Rock Inc. Annovis Bio, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 97,629 shares of ANVS stock, worth $811,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,629

Previous 95,984 1.71%

Holding current value

$811,296

Previous $1.79 Million 35.28%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.47 - $18.93 $13,933 - $31,139	1,645 Added 1.71%	97,629 $1.16 Million
Q4 2023 Feb 13, 2024	SELL	$5.55 - $19.62 $1,648 - $5,827	-297 Reduced 0.31%	95,984 $1.79 Million
Q3 2023 Nov 13, 2023	SELL	$9.37 - $14.12 $9,482 - $14,289	-1,012 Reduced 1.04%	96,281 $913,000
Q2 2023 Aug 11, 2023	BUY	$11.95 - $16.31 $36,411 - $49,696	3,047 Added 3.23%	97,293 $1.39 Million
Q1 2023 May 12, 2023	SELL	$12.33 - $22.1 $110,353 - $197,795	-8,950 Reduced 8.67%	94,246 $1.45 Million

Q4 2022 Feb 13, 2023	SELL	$10.99 - $13.55 $453,370 - $558,978	-41,253 Reduced 28.56%	103,196 $1.39 Million
Q3 2022 Nov 14, 2022	SELL	$10.26 - $21.81 $24,244 - $51,537	-2,363 Reduced 1.61%	144,449 $1.98 Million
Q2 2022 Aug 12, 2022	SELL	$8.61 - $13.87 $7,585 - $12,219	-881 Reduced 0.6%	146,812 $1.66 Million
Q1 2022 May 12, 2022	BUY	$11.84 - $19.78 $1,112 - $1,859	94 Added 0.06%	147,693 $1.97 Million
Q4 2021 Feb 10, 2022	BUY	$17.58 - $37.67 $778,249 - $1.67 Million	44,269 Added 42.84%	147,599 $2.6 Million
Q3 2021 Nov 09, 2021	BUY	$30.95 - $120.97 $72,206 - $282,223	2,333 Added 2.31%	103,330 $3.28 Million
Q2 2021 Aug 11, 2021	BUY	$21.55 - $96.1 $2.18 Million - $9.71 Million	100,997 New	100,997 $8.64 Million

Others Institutions Holding ANVS

# of Institutions

Shares Held

1.2M

Call Options Held

779K

Put Options Held

1.77M

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $67.8M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account